$PFE Options Intelligence

# 🎯 SELL PFE MAR 20 26/25 PUT SPREAD

I recommend this credit spread because the term structure reveals a critical opportunity: 30-day Clean IV at 31.4% sits 8.9% ABOVE the 22.5% baseline volatility, signaling overpriced options ideal for premium selling. Combined with smart money's bearish positioning (55% of whale activity), elevated IV Rank at 100%, and Pfizer's neutral RSI at 46.67, this creates a high-probability income trade with defined risk.[1][2]

Sell PFE Mar 20 26/25 Put Spread
Stock Price: $26.54 | Entry: $0.35 credit

📊 Trade Metrics

• Risk: $65 | Reward: $35 (54% return on risk)
• Breakeven: $25.65
• Max Loss: $65 if PFE < $25 at expiry
• Max Profit: $35 if PFE > $26 at expiry
• Win Rate: 68% (based on delta)
• Days to Expiration: 14

📈 Term Structure & Volatility Analysis

• Baseline 90-day Vol: 22.5%
• 10-day Clean IV: 28.7% (6.2% above baseline = SELL signal ✅)
• Market IV: 31.4% (8.9% event premium = STRONG SELL)
• Current IV Rank: 100% (Extremely elevated vs historical 14.6%)
• Calendar Opportunity: Yes - 10d IV significantly elevated vs 35d (27.4%)
• Recommendation: SELL premium NOW before IV compression

📈 Greeks & Volatility

• Net Delta: -0.30 (mildly bearish, but credit spread profits from decay)
• Theta: $2.50/day (strong time decay)
• Vega: +$12 (benefits from IV compression)
• Current IV: 31.4% vs Historical: 14.6%
• IV Rank: 100% (Extreme - massive premium to sell)
• Put/Call Ratio: 0.45 (Very bullish sentiment, but we're selling puts)

🎯 Why This Trade

The term structure is screaming SELL. The 10-day Clean IV of 28.7% sits nearly 9% above baseline volatility of 22.5%, indicating options are significantly overpriced relative to historical norms. This creates a statistical edge for premium sellers. According to Benzinga's smart money tracking, "Deep-pocketed investors have adopted a bearish approach towards Pfizer," with 55% of whale activity leaning bearish and targeting a price range of $18.0-$28.0 over three months.[1] This validates our bearish bias.

Current IV Rank of 100% is extreme—options are trading at the highest levels in years compared to historical volatility. The expected daily move of ±0.56 (2.13%) is modest, meaning the market is pricing in significant uncertainty despite the small daily range. This mismatch creates opportunity: we collect $35 credit while risking only $65, with 68% probability of profit.

Pfizer's RSI at 46.67 is neutral—no overbought/oversold extremes—suggesting the stock lacks directional conviction. The stock trades 2.2% below its 20-day MA ($27.13), indicating slight weakness. Price remains above the 200-day MA ($25.11), maintaining a bullish technical backdrop. However, the 2026 guidance disappointed with flat-to-negative growth due to declining COVID revenues ($5B vs $6.7B in 2025) and patent expirations costing $1.5B in revenue.[3]

The 14-day expiration captures maximum theta decay before earnings on May 5 (60 days away), avoiding event risk while profiting from daily time bleed.

📊 Pro Analysis

• Current IV: 31.4% vs Historical: 14.6% (114% premium!)
• IV Rank: 100% (Highest in years)
• Expected Daily Move: ±0.56 (2.13%)
• Put/Call Volume Ratio: 0.45 (Bullish, but we're selling puts for income)
• Market Maker Max Pain: $27 (above our short strike)
• Technical: RSI 46.67 (neutral), Price 2.2% below 20MA
• Unusual Activity: 2026-03-20 30 put: 800 volume vs 312 OI (2.6x normal)

🔍 Earnings Date Check

Earnings on May 5, 2026 (60 days away). ✅ Recommended expiration (Mar 20) is BEFORE earnings, which is PERFECT for this trade—we close the position 46 days before earnings, avoiding event risk entirely while capturing the current IV premium.

💡 Trade Management

• Entry: Sell at $0.35 credit (limit order)
• Target: Close at $0.15 (57% profit) by Mar 15
• Stop: Exit if PFE breaks below $25.50 (intrinsic risk)
• Time Stop: Close 3 days before expiration (Mar 17)

📅 Economic Events: CPI (Mar 11, 5 days), Fed Rate Decision (Mar 18, 12 days)

🔍 Market Overview

Pfizer faces a challenging macro backdrop. The Fed's current stance on potential rate cuts combined with elevated rates pressures dividend stocks. Pfizer's 6.48% dividend yield attracts income investors, but 2026 EPS guidance of $2.80-$3.00 represents a 13% decline from 2025's $3.22 due to COVID revenue collapse and patent expirations.[3] The company expects $3B+ in losses from patent cliffs in 2027.

However, the pipeline offers hope: 20 pivotal studies planned for 2026, including 10 for obesity candidates from the Metsera acquisition and four for dual PD-1/VEGF inhibitors. RSV vaccine Abrysvo grew 136% YoY to $481M in sales, partially offset by limited ACIP recommendations.

Sector peers